Ultragenyx Pharmaceutical (RARE) Non-Current Deferred Tax Liability (2017 - 2026)

Ultragenyx Pharmaceutical (RARE) has 10 years of Non-Current Deferred Tax Liability data on file, last reported at $30.0 million in Q1 2026.

• Quarterly Non-Current Deferred Tax Liability changed 0.19% year-over-year to $30.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.0 million (changed 0.19% YoY) and the FY2025 annual result came in at $30.0 million, changed 0.0% from the prior year.
• Non-Current Deferred Tax Liability held at $30.0 million in Q1 2026 per RARE's latest filing, from $30.0 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $33.3 million in Q1 2022 and bottomed at $30.0 million in Q4 2024.
• The 5-year median for Non-Current Deferred Tax Liability is $30.1 million (2023), against an average of $31.0 million.
• The widest annual swing landed in 2022, when Non-Current Deferred Tax Liability changed 0.0%; it then decreased 5.08% in 2023.
• Tracing RARE's Non-Current Deferred Tax Liability over 5 years: stood at $31.7 million in 2022, then declined by 5.08% to $30.1 million in 2023, then dropped by 0.19% to $30.0 million in 2024, then changed by 0.0% to $30.0 million in 2025, then changed by 0.0% to $30.0 million in 2026.
• Per Business Quant, the three latest RARE Non-Current Deferred Tax Liability figures stand at $30.0 million (Q1 2026), $30.0 million (Q4 2025), and $30.1 million (Q3 2025).

Peer Comparison